ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP) - Summary - MDSpire
Advertisement
ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP)
To evaluate the current real-world clinical practice regarding the use of ATG and other serotherapy in conditioning regimens for autologous HSCT in various autoimmune diseases across EBMT centers.
Key Findings:
46 EBMT centers (66%) from 18 countries participated in the survey.
All centers use ATG, with Cy-ATG being the most common regimen.
12 centers (26.1%) use rituximab in addition to ATG.
Thymoglobulin is the most frequently used type of ATG (89.1%).
ATG administration varies in timing and dosage, with most centers using a test dose.
Interpretation:
The survey highlights significant variability in the use of serotherapy and conditioning regimens for HSCT in autoimmune diseases, suggesting a need for standardized practices to optimize treatment outcomes and reduce variability in patient care.
Limitations:
Survey-based study may not capture all clinical nuances, potentially leading to incomplete understanding of practices.
Responses may vary based on center-specific practices and experiences, which could affect the generalizability of the findings.
Conclusion:
Standardizing ATG administration and conditioning regimens could enhance the efficacy and safety of HSCT in treating autoimmune diseases, ultimately improving patient outcomes.
